40
https://pubmed.ncbi.nlm.nih.gov/38091201
The review discusses the pharmacology, preclinical and clinical data of trastuzumab deruxtecan (T-DXd), a novel antibody-drug conjugate for HER2-expressing breast cancer, highlighting its robust activity, manageable toxicity and potential as an additional line for HER2-low disease.
